SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics to treat life threatening diseases. Its lead product candidate is ZADAXIN, which is in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. The company’s other drug development candidate is SCV-07, which is in clinical development for the treatment of viral and other infectious diseases. The company offers its products primarily in Asia, the Middle East, and Latin America. SciClone Pharmaceuticals was founded in 1989 and is headquartered in San Mateo, California.